Organization | RTOG Foundation

RTOG Foundation Report issue

Foundation Phase 1 Phase 2 Phase 3

Founded: Philadelphia PA United States (1997)

Organization Overview

First Clinical Trial

2016

NCT02764593

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

RTOG Foundation | RTOG Foundation, Inc.

Active Ingredients

Drugs in Phase 3 Trials (4)

cisplatin (platinol) (2 trials)

etoposide (vepesid) (1 trial)

lutetium (177Lu) vipivotide tetraxetan (Pluvicto) (1 trial)

nivolumab (opdivo) (2 trials)

Drugs in Phase 2 Trials (5)

anastrozole (arimidex) (1 trial)

bevacizumab (avastin) (1 trial)

bicalutamide (casodex) (1 trial)

enzalutamide (xtandi) (1 trial)

pembrolizumab (keytruda) (1 trial)

Drugs in Phase 1 Trials (1)

cetuximab (erbitux) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Squamous Cell (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Gliosarcoma (Phase 2)

Lung Neoplasms (Phase 3)

Prostatic Neoplasms (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 6
# of Trial APIs: 10